Martin Åmark

New Capabilities

Leading Xbrane into its first US launch, targeted for 2027

After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. Xbrane announced the approval on October 27, two days before the FDA's October 29 review deadline.

Updated Oct 31